<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Specific trials on adult Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and 'unclassifiable' <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with features intermediate between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) are advocated which include substantial numbers of older patients, to improve treatment feasibility, while countering risks of systemic and central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) recurrences </plain></SENT>
<SENT sid="1" pm="."><plain>We prospectively evaluated a modified CODOX-M/IVAC (CODOX-M: <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>; IVAC: ifosfamide, <z:chebi fb="0" ids="4911">etoposide</z:chebi> and high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>) regimen by the addition of rituximab (R) and liposome-encapsulated <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (D) to increase antitumour activity and halve the number of intrathecal treatments </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty adults (40% &gt;60years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (n=15) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (n=15) were accrued </plain></SENT>
<SENT sid="3" pm="."><plain>Primary endpoints were progression-free survival (PFS), <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence, and liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-associated toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty percent of patients received the whole treatment programme, the remaining cases received at least three full courses </plain></SENT>
<SENT sid="5" pm="."><plain>Application of the RD-CODOX-M/IVAC regimen resulted in remarkable 4-year PFS (78%) and complete remission (CR) rates (93%) </plain></SENT>
<SENT sid="6" pm="."><plain>However, PFS was significantly lower in patients older than 60years as compared to younger ones (49%vs 93%, P=0·03; median, 36months), despite high actual dose-intensity, CR rate and tolerability </plain></SENT>
<SENT sid="7" pm="."><plain>Reduced-intensity intratechal prophylaxis through liposomal <z:chebi fb="0" ids="28680">cytarabine</z:chebi> was effective because the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> failure rate was low (3·4%) and without severe neurological toxicities </plain></SENT>
<SENT sid="8" pm="."><plain>The RD-CODOX-M/IVAC strategy is feasible and highly effective, but improving outcomes in elderly patients remains a priority </plain></SENT>
</text></document>